All Articles

A large retrospective chart review found a short median progression-free survival in patients with non–small-cell lung cancer harboring the KRAS G12C mutation who were treated with docetaxel with or without ramucirumab.

Prisma Health Cancer Institute

Biomarker testing is associated with improved overall survival in patients with advanced non–small-cell lung cancer, but disparities in access to testing persist.

A review of treatments and clinical studies for non–small-cell lung cancer harboring the KRAS G12C mutation finds encouraging overall survival results.

Palliative care is underused by Black and Hispanic/Latinx patients with advanced non–small-cell lung cancer.

Evaluation of flat-dose nivolumab plus weight-based ipilimumab in patients with advanced non–small-cell lung cancer and poorer prognosis demonstrates efficacy with a tolerable safety profile.

The Commission on Cancer (CoC)—now 100 years old—is a consortium of professional organizations dedicated to improving survival and quality of life for patients with cancer through standard-setting, prevention, research, education, and the monitoring of comprehensive quality care, according to Frederick Greene, MD, FACS, a surgical oncologist at the Levine Cancer Institute in Charlotte, NC, and self-proclaimed “unabashed supporter of oncology nurse and patient navigators.

The March 2023 CATCH Is Awarded to Jennifer Mulholland, BSN, RN, OCN, GU, Nurse Navigator with St. Elizabeth Healthcare

When it comes to cancer genetic testing and counseling, role delineation between oncology nurse navigators, patient navigators, and genetic counselors is vital to avoiding overlap of responsibilities and delivering quality patient care.

A first-of-its-kind navigation acuity tool is entering a critical new phase of its development: an Institutional Review Board (IRB) quality initiative that will span 6 sites and include a minimum of 200 patients.